EVOFEM BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
EVOFEM BIOSCIENCES, INC. (EVFM) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $5.42 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2025-03-24
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2023-09-30 was $3.56M.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2023-06-30 was $499.00K.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2023-03-31 was $1.63M.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-06-30 was $11.02M.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2023 was $5.42M, a 303.27% increase from fiscal 2022.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2022 was $1.34M.
- EVOFEM BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $29.73M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $5.42M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | $3.56M 10-Q · filed 2024-11-14 | $4.06M derived: sum of 2 quarters · filed 2024-11-14 | $5.69M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $499.00K 10-Q · filed 2024-11-14 | $2.13M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $1.63M 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $1.34M 10-K · filed 2023-04-27 | ||||
| 2020-06-30 | $11.02M 10-Q · filed 2020-11-09 | ||||
| 2020-06-18 | $11.00M 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | $29.73M 10-K · filed 2021-03-04 |